Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells

Aurelia Rughetti, Ilenia Pellicciotta, Mauro Biffoni, Malin Bäckström, Thomas Link, Eric P. Bennet, Henrik Clausen, Thomas Noll, Gunnar C. Hansson, Joy M. Burchell, Luigi Frati, Joyce Taylor-Papadimitriou, Marianna Nuti

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Tumors exploit several strategies to evade immune recognition, including the production of a large number of immunosuppressive factors, which leads to reduced numbers and impaired functions of dendritic cells (DCs) in the vicinity of tumors. We have investigated whether a mucin released by tumor cells could be involved in causing these immunomodulating effects on DCs. We used a recombinant purified form of the MUC1 glycoprotein, an epithelial associated mucin that is overexpressed, aberrantly glycosylated, and shed during cancer transformation. The O-glycosylation profile of the recombinant MUC1 glycoprotein (ST-MUC1) resembled that expressed by epithelial tumors in vivo, consisting of large numbers of sialylated core 1 (sialyl-T, ST) oligosaccharides. When cultured in the presence of ST-MUC1, human monocyte-derived DCs displayed a modified phenotype with decreased expression of costimulatory molecules (CD86, CD40), Ag-presenting molecules (DR and CD1d), and differentiation markers (CD83). In contrast, markers associated with an immature phenotype, CD1a and CD206 (mannose receptor), were increased. This effect was already evident at day 4 of DC culture and was dose dependent. The modified phenotype of DCs corresponded to an altered balance in IL-12/IL-10 cytokine production, with DC expressing an IL-10highIL-12low phenotype after exposure to ST-MUC1. These DCs were defective in their ability to induce immune responses in both allogeneic and autologous settings, as detected in proliferation and ELISPOT assays. The altered DC differentiation and Ag presentation function induced by the soluble sialylated tumor-associated mucin may represent a mechanism by which epithelial tumors can escape immunosurveillance.

Original languageEnglish
Pages (from-to)7764-7772
Number of pages9
JournalJournal of Immunology
Volume174
Issue number12
Publication statusPublished - Jun 15 2005

Fingerprint

Dendritic Cells
Glycoproteins
Neoplasms
Mucins
Phenotype
CD1d Antigen
Tumor Escape
Enzyme-Linked Immunospot Assay
Immunologic Monitoring
Differentiation Antigens
Interleukin-12
Immunosuppressive Agents
Oligosaccharides
Glycosylation
Interleukin-10
Monocytes
Cell Differentiation
Cell Culture Techniques
Cytokines

ASJC Scopus subject areas

  • Immunology

Cite this

Rughetti, A., Pellicciotta, I., Biffoni, M., Bäckström, M., Link, T., Bennet, E. P., ... Nuti, M. (2005). Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. Journal of Immunology, 174(12), 7764-7772.

Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. / Rughetti, Aurelia; Pellicciotta, Ilenia; Biffoni, Mauro; Bäckström, Malin; Link, Thomas; Bennet, Eric P.; Clausen, Henrik; Noll, Thomas; Hansson, Gunnar C.; Burchell, Joy M.; Frati, Luigi; Taylor-Papadimitriou, Joyce; Nuti, Marianna.

In: Journal of Immunology, Vol. 174, No. 12, 15.06.2005, p. 7764-7772.

Research output: Contribution to journalArticle

Rughetti, A, Pellicciotta, I, Biffoni, M, Bäckström, M, Link, T, Bennet, EP, Clausen, H, Noll, T, Hansson, GC, Burchell, JM, Frati, L, Taylor-Papadimitriou, J & Nuti, M 2005, 'Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells', Journal of Immunology, vol. 174, no. 12, pp. 7764-7772.
Rughetti A, Pellicciotta I, Biffoni M, Bäckström M, Link T, Bennet EP et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. Journal of Immunology. 2005 Jun 15;174(12):7764-7772.
Rughetti, Aurelia ; Pellicciotta, Ilenia ; Biffoni, Mauro ; Bäckström, Malin ; Link, Thomas ; Bennet, Eric P. ; Clausen, Henrik ; Noll, Thomas ; Hansson, Gunnar C. ; Burchell, Joy M. ; Frati, Luigi ; Taylor-Papadimitriou, Joyce ; Nuti, Marianna. / Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. In: Journal of Immunology. 2005 ; Vol. 174, No. 12. pp. 7764-7772.
@article{fa2d052e2a714778b535c0d14274263c,
title = "Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells",
abstract = "Tumors exploit several strategies to evade immune recognition, including the production of a large number of immunosuppressive factors, which leads to reduced numbers and impaired functions of dendritic cells (DCs) in the vicinity of tumors. We have investigated whether a mucin released by tumor cells could be involved in causing these immunomodulating effects on DCs. We used a recombinant purified form of the MUC1 glycoprotein, an epithelial associated mucin that is overexpressed, aberrantly glycosylated, and shed during cancer transformation. The O-glycosylation profile of the recombinant MUC1 glycoprotein (ST-MUC1) resembled that expressed by epithelial tumors in vivo, consisting of large numbers of sialylated core 1 (sialyl-T, ST) oligosaccharides. When cultured in the presence of ST-MUC1, human monocyte-derived DCs displayed a modified phenotype with decreased expression of costimulatory molecules (CD86, CD40), Ag-presenting molecules (DR and CD1d), and differentiation markers (CD83). In contrast, markers associated with an immature phenotype, CD1a and CD206 (mannose receptor), were increased. This effect was already evident at day 4 of DC culture and was dose dependent. The modified phenotype of DCs corresponded to an altered balance in IL-12/IL-10 cytokine production, with DC expressing an IL-10highIL-12low phenotype after exposure to ST-MUC1. These DCs were defective in their ability to induce immune responses in both allogeneic and autologous settings, as detected in proliferation and ELISPOT assays. The altered DC differentiation and Ag presentation function induced by the soluble sialylated tumor-associated mucin may represent a mechanism by which epithelial tumors can escape immunosurveillance.",
author = "Aurelia Rughetti and Ilenia Pellicciotta and Mauro Biffoni and Malin B{\"a}ckstr{\"o}m and Thomas Link and Bennet, {Eric P.} and Henrik Clausen and Thomas Noll and Hansson, {Gunnar C.} and Burchell, {Joy M.} and Luigi Frati and Joyce Taylor-Papadimitriou and Marianna Nuti",
year = "2005",
month = "6",
day = "15",
language = "English",
volume = "174",
pages = "7764--7772",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells

AU - Rughetti, Aurelia

AU - Pellicciotta, Ilenia

AU - Biffoni, Mauro

AU - Bäckström, Malin

AU - Link, Thomas

AU - Bennet, Eric P.

AU - Clausen, Henrik

AU - Noll, Thomas

AU - Hansson, Gunnar C.

AU - Burchell, Joy M.

AU - Frati, Luigi

AU - Taylor-Papadimitriou, Joyce

AU - Nuti, Marianna

PY - 2005/6/15

Y1 - 2005/6/15

N2 - Tumors exploit several strategies to evade immune recognition, including the production of a large number of immunosuppressive factors, which leads to reduced numbers and impaired functions of dendritic cells (DCs) in the vicinity of tumors. We have investigated whether a mucin released by tumor cells could be involved in causing these immunomodulating effects on DCs. We used a recombinant purified form of the MUC1 glycoprotein, an epithelial associated mucin that is overexpressed, aberrantly glycosylated, and shed during cancer transformation. The O-glycosylation profile of the recombinant MUC1 glycoprotein (ST-MUC1) resembled that expressed by epithelial tumors in vivo, consisting of large numbers of sialylated core 1 (sialyl-T, ST) oligosaccharides. When cultured in the presence of ST-MUC1, human monocyte-derived DCs displayed a modified phenotype with decreased expression of costimulatory molecules (CD86, CD40), Ag-presenting molecules (DR and CD1d), and differentiation markers (CD83). In contrast, markers associated with an immature phenotype, CD1a and CD206 (mannose receptor), were increased. This effect was already evident at day 4 of DC culture and was dose dependent. The modified phenotype of DCs corresponded to an altered balance in IL-12/IL-10 cytokine production, with DC expressing an IL-10highIL-12low phenotype after exposure to ST-MUC1. These DCs were defective in their ability to induce immune responses in both allogeneic and autologous settings, as detected in proliferation and ELISPOT assays. The altered DC differentiation and Ag presentation function induced by the soluble sialylated tumor-associated mucin may represent a mechanism by which epithelial tumors can escape immunosurveillance.

AB - Tumors exploit several strategies to evade immune recognition, including the production of a large number of immunosuppressive factors, which leads to reduced numbers and impaired functions of dendritic cells (DCs) in the vicinity of tumors. We have investigated whether a mucin released by tumor cells could be involved in causing these immunomodulating effects on DCs. We used a recombinant purified form of the MUC1 glycoprotein, an epithelial associated mucin that is overexpressed, aberrantly glycosylated, and shed during cancer transformation. The O-glycosylation profile of the recombinant MUC1 glycoprotein (ST-MUC1) resembled that expressed by epithelial tumors in vivo, consisting of large numbers of sialylated core 1 (sialyl-T, ST) oligosaccharides. When cultured in the presence of ST-MUC1, human monocyte-derived DCs displayed a modified phenotype with decreased expression of costimulatory molecules (CD86, CD40), Ag-presenting molecules (DR and CD1d), and differentiation markers (CD83). In contrast, markers associated with an immature phenotype, CD1a and CD206 (mannose receptor), were increased. This effect was already evident at day 4 of DC culture and was dose dependent. The modified phenotype of DCs corresponded to an altered balance in IL-12/IL-10 cytokine production, with DC expressing an IL-10highIL-12low phenotype after exposure to ST-MUC1. These DCs were defective in their ability to induce immune responses in both allogeneic and autologous settings, as detected in proliferation and ELISPOT assays. The altered DC differentiation and Ag presentation function induced by the soluble sialylated tumor-associated mucin may represent a mechanism by which epithelial tumors can escape immunosurveillance.

UR - http://www.scopus.com/inward/record.url?scp=20444403424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444403424&partnerID=8YFLogxK

M3 - Article

C2 - 15944279

AN - SCOPUS:20444403424

VL - 174

SP - 7764

EP - 7772

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -